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Abstract
Purpose The purpose of this study was to investigate the
activity of capecitabine and trastuzumab in patients with
HER2-overexpressing metastatic breast caner resistant to
both anthracyclines and taxanes.
Method From June 2003 and May 2006, 40 female
patients with measurable or assessable metastatic breast
cancer were enrolled and data from 38 patients were
reviewed extramurally and analyzed. Patients were treated
with weekly trastuzumab given at a dose of 2 mg/kg/day
over 90 min (4 mg/kg/day on the Wrst infusion) and capecit-
abine given at a dose 1,657 mg/m2/day during 21 days with
a subsequent pause of 7 days. This cycle was repeated
every 28 days. The primary endpoint was overall survival
and secondary endpoints were progression-free survival
and response rate.
Result A median of 4.5 cycles (range 1–9 cycles) were
delivered. The median age was 53 (range 30–69 years).
Median overall survival and progression-free survival was
22.3 and 4.1 months, respectively. Survival rate at 1 and
2 year was 81.6 and 47.4%, respectively. Response rate was
18.4% (95% CI, 7.7–34.3%). All evaluable patients have
responded with two CR (5.3%), 5 PR (13.2%), 20 SD
(52.6%), 8 PD (21.1%) and 3 NE (7.9%). Regarding the
hematological toxicities, grade 1/2/3 neutropenia, grade 1/2
anemia, grade 1 thrombocytopenia and grade 1/2 liver dys-
function were also common. No treatment-related death
was reported.
Conclusion The combination of capecitabine and trast-
uzumab is active and well-tolerated in patients with HER2-
overexpressing breast caner resistant to both anthracyclines
and taxanes.
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Introduction
Despite improvements in survivability of nonmetastatic
breast cancer patients over the past 25 years, particularly
for both estrogen receptor (ER)-positive and human epider-
mal growth factor receptor 2 (HER2)-positive disease, met-
astatic breast cancer remains an incurable disease [1, 2].
When the disease recurred, the decision to choose a certain
therapy is usually based on tumor biology, symptoms, met-
astatic pattern, time to disease recurrence, and patient
desire [3].
For metastatic breast cancer the initial treatment with
anthracycline-based chemotherapy and/or taxane-based
therapy is considered as standard [4, 5], whereas the out-
come is still poor at present. Therefore, the new avenue for
breakthrough in treatments is required to provide. One of
the possible approaches is to use molecular targeting ther-
apy. Breast cancers that make high levels of the transmem-
brane protein kinase HER2 (i.e., those that overexpress
HER2) have a poorer prognosis as compared to those that
either do not make this protein or make lower levels [6]. It
is important that overexpression of HER2 also identiWes
those women who may beneWt from the targeted drug trast-
uzumab, and those who do better with chemotherapy regi-
mens that contain a drug of the anthracycline class [6]. The
humanized monoclonal antibody trastuzumab, which tar-
gets the human HER2, is an eVective treatment for patients
with HER2 overexpression, which comprises approxi-
mately 15–25% of all breast cancers [7,  8]. Meanwhile,
capecitabine (N4-pentyloxycarbonyl-5deoxy-5-Xuorocyti-
dine), an orally administered prodrug of Xuorouracil (FU),
is also a highly active and well-tolerated treatment option
for metastatic breast cancer. Capecitabine is the therapy
speciWcally approved for anthracycline- and taxane-
exposed patients, a setting that is becoming increasingly
important as more patients have recurrent metastatic
disease after receiving adjuvant anthracycline and taxane
therapy [9–12]. The combination of capecitabine and
trastuzumab might achieve improved eYcacy in patients
with HER2-positive metastatic breast cancer without com-
promising tolerability [13–15].
Recently, Schaller et al. [13] reported that the combina-
tion of capecitabine and trastuzumab is highly active in
patients with HER2-overexpressing anthracycline- and/or
taxane-pretreated breast caner. However, to date, no studies
have investigated the activity of capecitabine and trast-
uzumab in patients with HER2-overexpressing breast caner
resistant to both anthracyclines and taxanes. In the present
study, we evaluate the activity and safety of this two-agent
combination therapy in patient, resistant to both anthracy-
clines and taxanes.
Patients and methods
Eligibility criteria
To be eligible for the study, patients had to meet the follow-
ing criteria: age greater than 20 years and less than
75 years; histologically proven breast cancer with HER2
overexpressing progressive metastatic disease; resistance to
both anthracyclines and taxanes for metastatic and
advanced disease as described in below, resistance deWni-
tion section; at least one measurable tumor site (target
lesion) with index lesions on physical examination, X-ray,
ultrasound, or computed tomography scan; Eastern Cooper-
ative Oncology Group (ECOG) performance status of 0–2;
estimated life expectancy ¸3 months; reasonable bone
marrow function (neutrophil count ¸ 1,500/L, platelet
count ¸ 100,000/L, and hemoglobin levels ¸ 9g / d L ) ;
adequate hepatic and renal function, including AST and
ALT twice (in cases of liver metastasis, three times) the
upper limit of normal, bilirubin 1.5 g/dL, alkaline phospha-
tase 2.5 times the upper limit of normal, serum creatine
1.2 mg/dL, and basal creatine clearance 50 mL/min; no evi-
dence of cardiac dysfunction (LV ejection fraction > 50%).
This capecitabine and trastuzumab combination regimen
was eligible for patients in third line of therapy, resistant to
both anthracyclines and taxanes. Hormonal therapy, in the
neoadjuvant or adjuvant setting or for advanced disease,
was permitted, but concomitant hormone therapy was not
allowed. Moreover, prior trastuzumab was allowed. Brain
or leptomeningeal involvement was not allowed. Written
informed consent was obtained before registration. The
HER2 status was assessed at study entry by immunohisto-
chemistry (IHC) and/or Xuorescence in situ hybridization
(FISH). Patients with HER2-receptor overexpression at the
3+ level (Hercep Test; DakoCytomation, Capenteria, CA,
USA) were immediately eligible for inclusion. A HER2
expression at the 2+ level required conWrmation by the
proof of a HER2 gene ampliWcation by FISH. HER2 testing
was performed on a sample of the primary tumor or a
biopsy of a metastatic site. HER2 status was examined by
the pathologists of each institution participated in this
study. The FISH ratio was assessed as the number of genes
proportional to the number of centromeres. The HER2 was
considered ampliWed when the FISH signal ratio of HER2
was 2 and more. Exclusion criteria included pretreatmentCancer Chemother Pharmacol (2009) 64:361–369 363
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with capecitabine (Xeloda; HoVman La, Rosche AG);
hypersensitivity to trastuzumab (Herceptin; HoVman-La
Rosche AG, Basal, Switzerland), Xuoropyrimidines, cape-
citabine, or any other substance of the drug preparation;
known lack of dihydropyrimidine dehydrogenase; local
resection or irradiation of the marker lesion after study
entry; additional systemic antitumor therapy study; preg-
nancy or breastfeeding.
All data were managed and analyzed in a central data
coordinating division located at the Foundation for Biologi-
cal Research and Innovation, Translational Research Infor-
matics Center, Kobe, Japan.
DeWnition of both anthracycline and taxane resistance
We used Ando’s deWnition [16] for reference to determine
the primary resistance and secondary resistance to chemo-
therapeutic agents. All patients must not have received only
anthracyclines, but also taxanes for metastatic disease. Pri-
mary resistance to anthracycline or taxane was deWned as
progressive disease during or within 6 months after com-
pletion of anthracycline or taxane, respectively. Patients
without any documented tumor response to Wrst-line
chemotherapy that included anthracyclines or taxanes for
metastatic disease also were classiWed as having primary
resistance. Patients whose disease progressed more than
6 months after completion of anthracycline or taxane were
treated as a Wrst-line regimen for metastatic disease. Second-
ary resistance was deWned as disease progression among
6–12 months after a documented clinical response to Wrst-line
chemotherapy with anthracyclines or taxanes for metastatic
disease. Secondary resistance was further divided into three
categories as follows: (a) absolute resistance: disease pro-
gression during treatment with regimens that contained
anthracycline or taxane after a period after completion of the
chemotherapy; (b) relative resistance: disease progression
within 6 months after complete of the chemotherapy; and
(c) sensitive regrowth: disease progression more than
12 months after completion of the chemotherapy.
Therapy
Trastuzumab was administered at an initial dose of 4 mg/kg
body weight and was administered subsequently at weekly
doses of 2 mg/kg body weight during 90 min. Capecitabine
was administered during 21 days with a subsequent pause
of 7 days. The daily dose was 1,657 mg/m2 administered in
equal parts in the morning and in the evening. This cycle
was repeated every 28 days for six cycles. Trastuzumab
was discontinued while capecitabine was held. When cape-
citabine was withdrawn, a new treatment cycle was consid-
ered. Trastuzumab and capecitabine were administered
until disease progression or unacceptable toxicity.
If capecitabine-associated toxicity occurred, dosage
reduction and delayed were permitted.
1. If a grade 2 toxicity occurred, the therapy was inter-
rupted immediately until the symptoms disappeared
completely. At that time, the medication was continued
at a 75% level until six cycles. The level was never
increased. If a grade 2 or 3 toxicity occurred again, this
process was allowed once more until six cycles, at
which point the medication was continued at a 50%
level. The level was never increased. If a grade 4 toxic-
ity occurred again, the therapy was interrupted immedi-
ately. The treatment was discontinued when the patient
developed signs of toxicity for a third time.
2. At the beginning of the treatment, if a grade 3 toxicity
occurred, the therapy was stopped immediately until
the symptoms disappeared completely. At that time,
the medication was continued at a 50% level until six
cycles. The level was never increased. If a grade ¸2
toxicity occurred again, the treatment was discontin-
ued.
3. At the beginning of the treatment, if a grade 4 toxicity
occurred, the therapy was stopped immediately.
A dose modiWcation of trastuzumab was not allowed. Mild
antiemetic drugs, such as metoclopramide and dexametha-
sone, and mild antidiarrheal drugs, such as loperamide
hydrochloride were administered, if necessary. Trast-
uzumab was discontinued if patients developed congestive
heart failure or the LVEF fell below 45%. The decision to
discontinue trastuzumab at that point was discussed with
the patient after the risks and potential beneWts of trast-
uzumab therapy were assessed. Granulocyte colony-stimu-
lating factor, to prevent febrile neutropenia was allowed, if
grade ¸ 3 leukopenia occurred, and blood or platelet trans-
fusion was allowed, if grade ¸ 3 anemia or thrombocytope-
nia occurred.
Assessment
The pretreatment evaluation included medical history and
physical examination, complete blood cell count, serum
chemistries, liver function tests, ECG, echocardiography,
tumor marker evaluation (CA15-3, CEA), hormone recep-
tor status (ER, PgR, HER2), and staging studies appropriate
to deWne the extent of metastatic disease, which included
chest X-ray, abdominal ultrasound, brain, thoracic and/or
abdominal computed tomography scan, and bone scan.
Antitumor activity was evaluated every two cycles on all
measurable lesions, and all patients were scheduled for at
least a 2-week treatment to be eligible for assessment of
tumor response. In patients with tumor response or stable
disease, the treatment was planned to be continued for up to
six cycles; thereafter, maintenance or no therapy was based364 Cancer Chemother Pharmacol (2009) 64:361–369
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on the clinician’s choice. After the completion of the treat-
ment plan, the patients were monitored every two cycles.
Clinical monitoring, complete blood cell count, serum
chemistries, and liver function tests were performed every
2 weeks until six cycles, and thereafter every 12 weeks.
Repeated multigated acquisition (MUGAs) or echocardio-
grams were performed after completion of cycle 2, 4, and 6,
and thereafter every 12 weeks, if the medication is contin-
ued. Patients were evaluated for toxicity, graded according
to the National Cancer Institute Common Toxicity Criteria
version 2.0 [17].
Tumor response was evaluated according to the response
evaluation criteria in solid tumors (RECIST) [18]. Progres-
sion-free survival was deWned from the Wrst day of treat-
ment to the identiWcation date of recurrence of cancer or
death from any cause. Overall survival was dated from the
Wrst day of treatment until death or was censored on the
date of the last follow-up appointment.
Statistical analysis
The primary endpoint of the study was the assessment of
the overall survival. Secondary endpoints were the determi-
nation of the progression-free survival and response rate. In
this trial, the targeted patients resistant to both anthracy-
cline and taxane had highly dismal disease, whose 1 year
survival was estimated <33% [16], thereby overall survival
was chosen for the primary endpoint. The recent paper [19]
reported that overall survival should be viewed as the end-
point of choice to assess the eYcacy of new treatments in
advanced breast cancer. The regimen would have been con-
sidered promising if the true 1-year survival were 50% or
higher in conjunction with acceptable toxicity, and would
be considered of no further interest if the true 1-year sur-
vival were 33% or lower. With 63 patients, the power of a
two-sided 0.05-level test is 80%. However, the power was
reduced to 62% because only 40 patients were enrolled in
the study. Survival curves were estimated using the Kap-
lan–Meier method. To test the diVerences of the survival
curves among subgroup of patients, the log-rank test was
used. All statistical analyses were performed using the SAS
version 9.1(SAS Institute, Inc, Cary, NC, USA). All tests
were two-sided, and a P<0 . 0 5  was considered statistically
signiWcant.
Results
Patients characteristics
From June 2003 to May 2006, 40 patients with metastatic
and HER2-overexpressing breast cancer, which was deW-
ned as the primary resistance or secondary resistance to
both anthracycline and taxane, were entered onto the study.
One patient was declared ineligible after registration: one
patient was treated oV-protocol immediately after enroll-
ment. Thirty-eight patients were reviewed extramurally and
analyzed. The demographic data, numbers of metastatic
tumor, and prior therapies are listed in Table 1. The median
age was 53 years (range 30–69 years), and Eastern Cooper-
ative Oncology Group performance status was good (0 or 1
in 95% of cases). Regarding prior treatments, 18 patients
were given anthracycline as neoadjuvant or adjuvant che-
motherapy and 19 patients for metastatic disease. In addi-
tion, 9 patients were given taxane as neoadjuvant or
adjuvant chemotherapy and 28 patients for metastatic dis-
ease. Resistance to previous chemotherapies (anthracy-
cline/taxane) was 7 patients (18%) with primary resistance/
primary resistance, 11 with (29%) with primary/secondary,
6 (16%) with secondary/primary, 11 (29%) with secondary/
secondary, and 3 (8%) with unknown, respectively. Pre-
dominate sites of metastasis were found in 37 cases (97%).
27 patients (71%) had one metastatic site, and 10 patients
(26%) had multiple metastases involving two or more
organ systems; 17 lung (45%), 10 liver (26%), 5 bone
(13%), 2 skin (5%), and 4 other sites (10.5%), respectively.
34 (90%) of the patients had invasive ductal carcinomas, 3
patients (8%) had cancers of other types, but the histopa-
thological type of one patient (3%) was unknown. Seventy
nine percent of patients had a past history of prior therapy
of trastuzumab.
Treatment activity
A median of 4.5 cycles (range 1–9 cycles) of treatment
were delivered. The median dose of capecitabine was
227,400 mg/body (range 2,400–453,600 mg/body) and the
median dose of trastuzumab was 1.28 mg/m2/week (range
0.31–1.51 mg/m2/week). Median follow-up time was
22.4 months (range 0.4–50.6 months). Median overall sur-
vival and progression-free survival of the entire group were
22.3 and 4.1 months, respectively (Fig. 1). Survival at 1
and 2 year was 81.6% (95% CI, 65.2–90.8%) and 47.4%
(95% CI, 31.0–62.1%), respectively. The best responses
recorded for each patient are listed in Table 2. A response
rate (CR or PR) was recorded in 7 of 38 women (18.4%;
95% CI, 7.7–34%): 2 patients (5%) achieved a CR, and 5
patients (13%) achieved a PR. SD was observed in 20
patients (53%), and PD was observed in 8 (21%). Clinical
beneWt rate (CBR: CR or PR or SD >/=24 weeks) was
21.1% (95% CI (conWdence interval), 9.6–37.3%). All
patients were treated previously with both anthracyclines
and taxanes. According to the previous treatment, a tumor
response was obtained in 18 (47%) of 38 cases previously
submitted to anthracycline-containing regimens and in 22
(58%) of 38 cases submitted to taxane-containing regimens.Cancer Chemother Pharmacol (2009) 64:361–369 365
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13 (34%) or 10 (26%) of 38 patients had progressive dis-
ease during the treatment with anthracyclines or taxanes,
respectively. There was no diVerence in overall survival in
patients with and without history of trastuzumab (P=0.80).
Anthracycline or taxane resistance and response 
to capecitabine and trastuzumab combination 
chemotherapy
The response rates of patients with primary and secondary
resistance of anthracycline and taxane are shown in
Table 3. There was no diVerence in response rate between
primary and secondary resistance in anthracycline and tax-
ane pretreated patients, respectively (P=0.73).
Toxicity
Associated side eVects are reported in Table 4; on the
whole, they were mild. There were no treatment-related
deaths. Regarding the hematological toxicities, neutropenia
occurred in 19 patients but was grade 3 only in 2 patients
(5%). Thrombocytopenia was rather uncommon, occurring
Table 1 Patient Characteristics
a Eastern Cooperative Oncology Group
No. of 
patients
%
No. 38
Age, years
Median 53
Range 30–69
Performance statusa
0 31 81.6
15 1 3 . 2
2 2 5.3
Menopausal status
Premenopause 12 31.6
Postmenopause 26 68.4
Receptor status
Estrogen receptor
Positive 7 18.4
Negative 31 81.6
Progesterone receptor
Positive 6 15.8
Negative 31 81.6
Unknown 1 2.6
Resistance to previous chemotherapies 
(Anthracycline/Taxane)
Primary resistance/Primary resistance 7 18.4
Primary resistance/Secondary resistance 11 29.0
Secondary resistance/Primary resistance 6 15.8
Secondary resistance/Secondary 
resistance
11 29.0
Unknown 3 7.9
Prior trastuzumab
Yes 30 78.9
No 8 21.2
Histology
Invasive ductal carcinomas 34 89.5
Other 3 7.9
Unknown 1 2.6
Number of metastasis
1 27 71.1
¸2 10 26.3
Unknown 1 2.6
Primary metastatic sites
Lung 17 44.7
Liver 10 26.3
Bone 5 13.2
Skin 2 5.3
Peritoneum 1 2.6
Mediastinum 1 2.6
Pleura 1 2.6
Unknown 1 2.6
Fig. 1 Overall survival curve (solid line) and progression-free sur-
vival curve (dot line) of patients with HER2 overexpressing metastatic
breast cancers with capecitabine and trastuzumab combination chemo-
therapy resistant to both anthracyclines and taxanes
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Table 2 Response to therapy (n =3 8 )
CI conWdence interval, CR complete response, PR partial response,
SD stable disease for 6 weeks, PD progressive disease
Response No. of Patients %
Complete response 2 5.3
Partial response 5 13.2
Stable disease 20 52.6
Progressive disease 8 21.1
Not evaluated 3 7.9
Response rate 18.4% (95% CI, 
7.7–34.3%)
Clinical beneWt rate 
(CBR = CR + PR + SD >/=24 weeks)
21.1% (95% CI, 
9.6–37.3%)366 Cancer Chemother Pharmacol (2009) 64:361–369
123
(grade 1) in only two case (5%). Seven patients developed
grade 2 anemia (18%). Grade ¸ 4 hematologic toxicity was
not observed. No patient developed a documented infec-
tion, and none required hospitalization owing to toxicity.
Moreover, grade 1/2 liver dysfunction (elevated AST, ALT,
ALP, -GTP, and T-bil) was common (45, 34, 50, 34, and
42%), and grade 1/2 hypercalcemia and hypoalbuminemia
was also common (45 and 32%). Regarding the nonhemato-
logical toxicities, the most common adverse events were
hand–foot syndrome (grade1/2/3 in 24; 63%), fatigue
(grade1/2 in 12; 32%), and diarrhea (grade 1/2/3 in 9;
24%). Mucositis occurred in 11 patients (grade 1 in 10;
29%). Serious adverse eVects occurred in three patients
(7.9%, 95% CI, 1.7–21.4%): 2 died of breast cancer and
one died of accidental asphyxia. Twenty-three patients dis-
continued therapy because of disease progression in 13,
physician’s discretion in 4, adverse eVects in 4 (grade 3
neutropenia at cycle 2, grade 2 general fatigue at cycle 2,
and grade 3 hand–foot syndrome at cycle 2 and 5), and
death in 2.
Discussion
We have detected three reports concerning the activity of
capecitabine and trastuzumab in anthracyclines or taxanes-
pretreated patients with HER2-overexpressing breast caner
[13–15]. However, there is no prospective study describing
the activity of capecitabine and trastuzumab in patients
with HER2-overexpressing breast caner resistant to both
anthracyclines and taxanes. This is the Wrst report that the
combination of capecitabine and trastuzumab is active in
patients with HER2-overexpressing breast caner resistant to
both anthracycline and taxane. Moreover, we could
observed that among the patients with the primary and sec-
ondary resistant to anthracycline and taxane, there was no
diVerence in response rate.
In recent studies of various chemotherapeutic agents for
breast cancer patients after failure of both anthracycline and
taxanes, the median overall survival was 12.8 months with
capecitabine alone [8], 7.8 months with gemcitabine alone
[20], 7.4 months with gemcitabine and cisplatin [21], and
10.3 months with gemcitabine and pemetrexed [22]. In the
present study, we suggested that the median overall sur-
vival was prolonged to 22.3 months with the combination
of capecitabine and trastuzumab for patients resistant to
both anthracyclines and taxanes. Therefore, we speculate
that trastuzumab with capecitabine can increase the overall
survival in patients with these HER2 overexpressing meta-
static breast cancers. For such category of patients, one
phase II study of trastuzumab plus gemcitabine in both
anthracycline and taxane-pretreated patients with meta-
static breast cancer, the median overall survival was
reported to be 14.7 months [23]. Further, Fig. 1 shows that
79% of the patients enrolled in the present study had a past
history of trastuzumab administration. Very recently,
Minckwitz et al. [24] reported a higher eYcacy for contin-
uing trastuzumab beyond trastuzumab progression when
second-line chemotherapy with capecitabine was initiated.
Until recently relative few clinical data were available
concerning the combination of trastuzumab with capecita-
bine. Osako et al. [14] retrospectively evaluated the eYcacy
and safety of combination therapy of trastuzumab plus
capecitabine in heavily pretreated patients with HER2-posi-
tive metastatic breast cancer. They investigated objective
response rate, clinical beneWt rate, and time-to-treatment
failure according to RECIST. A total of 49 patients were
assessed and median follow-up time of patients was
16.2 months (1.4–43.5 months). Objective response rate
was 16% (95% CI: 7–30%) and clinical beneWt rate was
47% (95% CI: 32–62%). Median time-to-treatment failure
was 5.4 months. Osako’s report suggests the combination
therapy of trastuzumab plus capecitabine was active and
tolerable for heavily pretreated patients with HER2-posi-
tive metastatic breast cancer. The combination therapy with
capecitabine and trastuzumab has been used by the other
investigators as a Wrst-line [25] or second-line [13] treat-
ment for metastasis from breast cancer. Patients receiving
trastuzumab and capecitabine as Wrst-line therapy had a
longer time to disease progression than did patients receiv-
ing this treatment as second- or third-line therapy (median
time to disease progression, 9.3 vs. 6.7 months, P <0 . 0 5 ) ,
but did not have longer overall survival (median overall
survival, 26.0 vs. 28.0 months).
As to the toxicities of the combination therapy with
capecitabine and trastuzumab, Schaller et al. [13] reported
Table 3 Response rates classiWed by anthracycline or taxane resistance category
C ConWdence interval. There was no diVerence in response rate among each group (P =0 . 7 3 )
Anthracycline/
Taxane
Primary resistance/
Primary resistance
Primary resistance/
Secondary resistance
Secondary resistance/
Primary resistance
Secondary resistance/
Secondary resistance
No. of patients 7 11 6 11
Response rate (%) 1/7 (14.3) 2/11(18.2) 2/6 (33.3) 1/11(9.1)
95% CI 0.4–57.9 2.3–51.8 4.3–77.7 0.2–41.3Cancer Chemother Pharmacol (2009) 64:361–369 367
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Table 4 Toxicity results Toxicity gradea G r a d e  1G r a d e  2G r a d e  3G r a d e  4
No. of 
patients (%)
No. of 
patients (%)
No. of 
patients (%)
No. of 
patients (%)
Hematological toxicity
Anemia 1 (2.6) 7 (18.4) 0 0
Leucocytopenia 1 (2.6) 6 (15.8) 0 0
Neutropenia 11 (28.9) 6 (15.8) 2 (5.3) 0
Thrombocytopenia 2 (5.3) 0 0 0
Elevated ALP 17 (44.7) 2 (5.3) 0 0
Elevated AST 14 (36.8) 3 (7.9) 0 0
Elevated ALT 12 (31.6) 1 (2.6) 0 0
Elevated -GTP 8 (21.1) 3 (7.9) 2 (5.3) 0
Elevated T-Bil 11 (28.9) 5 (13.2) 0 0
Elevated creatinine 1 (2.6) 0 0 0
Hypercalcemia 16 (42.1) 1 (2.6) 0 0
Hypoalbuminemia 12 (31.6) 0 0 0
Nonhematological toxicity
Hand–foot syndrome 16 (42.1) 5 (13.2) 3 (7.9) 0
Mucositis 11 (28.9) 0 0 0
Nausea 8 (21.1) 0 0 0
Vomiting 4 (10.5) 0 0 0
Diarrhea 7 (18.4) 1 (2.6) 1 (2.6) 0
Constipation 0 0 1 (2.6) 0
Abdominal pain 1 (2.6) 0 0 0
Edema 3 (7.9) 0 0 0
Rash 1 (2.6) 0 0 0
Hyperpigmentation 5 (13.2) 0 0 0
Pruritus 1 (2.6) 0 0 0
Injection site reaction 1 (2.6) 0 0 0
Nail changes 1 (2.6) 1 (2.6) 0 0
Ulceration 1 (2.6) 0 0 0
Cervical pain 1 (2.6) 0 0 0
Chest pain 2 (5.3) 0 0 0
Cough 2 (5.3) 1 (2.6) 0 0
Sputum 0 1 (2.6) 0 0
Dyspnea 0 1 (2.6) 0 0
Fever 3 (7.9) 1 (2.6) 0 0
Fatigue 10 (26.3) 2 (5.3) 0 0
Appetite loss 2 (5.3) 1 (2.6) 0 0
Weight loss 0 1 (2.6) 0 0
Headache 5 (13.2) 0 0 0
Dizziness 1 (2.6) 0 0 0
Voice changes 1 (2.6) 0 0 0
Impaired motor function 4 (10.5) 0 0 0
Photophobia 0 1 (2.6) 0 0
Cataract 0 1 (2.6) 0 0
Back pain 1 (2.6) 0 0 0
Urinary retention 1 (2.6) 0 0 0
Pain on urination 1 (2.6) 0 0 0
a According to National 
Cancer institute common 
Toxicity Criteria368 Cancer Chemother Pharmacol (2009) 64:361–369
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that the safety proWle of this combination was favorable for
breast cancer patients with HER2-overexpressing anthracy-
cline- and/or taxane-pretreated breast caner. The most com-
mon adverse events were pain, hand–foot syndrome, and
gastrointestinal toxicities. In the present study, we con-
Wrmed that this combination therapy was safe and well tol-
erated regimen. Moreover, the present study suggested that
grade 1/2 liver dysfunction (elevated AST, ALT, ALP,
-GTP, and T-bil) was common in the combination therapy
of capecitabine and trastuzumab. As to the hematological
toxicities, grade1/2 anemia occurred in 21% patients in the
present trial versus 68% in Schaller’s trial, but grade 3/4
anemia in 5% versus 8% patients. Moreover, regarding the
nonhematological toxicities, grade 1/2 hand–foot syn-
drome, one of the most common adverse events, occurred
in 55% patients in this present trial versus 68% in Schal-
ler’s trial, but grade 3/4 in 8 versus 16% patients. Because it
was reported that no clinically relevant diVerences in the
pharmacokinetics of capecitabine and its key metabolites
5-DFUR, 5-DFCR, and 5-FU were found between Japa-
nese and Caucasian patients [26], the lower incidence of
toxicity observed in our study may be due to the diVerence
of total doses of capecitabine between the present trial and
Schaller’s trial: the total dose of the present trial [about
156,586 mg/m2: 1,657 mg/m2 £ 21 days £ 4.5 (median
treatment cycles)] versus that of Schaller’s trial (about
280,000 mg/m2: 2,500 mg/m2 £ 14 days £ 8 (median
treatment cycles)). The reason why we selected a dose
1,657 mg/m2/day during 21 days with a subsequent pause
of 7 days as given capecitabine was rigorously based on the
previous result in Japan [27]. There were no diVerences in
response rate (20 vs. 20%) and median time to disease pro-
gression (2.8 vs. 3.0 months) between the diVerent drug
administrations from Japan and US [8, 27]. Consistent with
this, further investigations are needed to assess the safety in
additional clinical trials.
In conclusion, the combination of capecitabine and
trastuzumab is active and well-tolerated in patients with
HER2-overexpressing breast cancer well deWned resis-
tance to both anthracyclines and taxanes. Although at
present, the other chemotherapeutic agents such as vino-
relbine and oxaliplatin are under way for such category
group disease [28], our results suggest that this combina-
tion therapy may be established as a third line chemother-
apy for these breast cancer patients, by using the overall
survival as primary endpoint and the progression-free sur-
vival and response rate as secondary endpoints, because
the targeted patients in the present study had highly dismal
disease.
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